{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:00:04Z","timestamp":1774522804812,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T00:00:00Z","timestamp":1349913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00280-012-1996-6","type":"journal-article","created":{"date-parts":[[2012,10,11]],"date-time":"2012-10-11T00:06:04Z","timestamp":1349913964000},"page":"193-202","source":"Crossref","is-referenced-by-count":18,"title":["Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug\u2013drug interaction potential"],"prefix":"10.1007","volume":"71","author":[{"given":"Patricia M.","family":"LoRusso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Mita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Dimitrios","family":"Colevas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Malhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Colburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,11]]},"reference":[{"key":"1996_CR1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nm1614","volume":"13","author":"C Dierks","year":"2007","unstructured":"Dierks C, Grbic J, Zirlik K et al (2007) Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 13:944\u2013951","journal-title":"Nat Med"},{"key":"1996_CR2","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1210\/en.2004-0079","volume":"145","author":"L Fan","year":"2004","unstructured":"Fan L, Pepicelli CV, Dibble CC et al (2004) Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology 145:3961\u20133970","journal-title":"Endocrinology"},{"key":"1996_CR3","doi-asserted-by":"crossref","first-page":"12125","DOI":"10.1074\/jbc.271.21.12125","volume":"271","author":"H Hahn","year":"1996","unstructured":"Hahn H, Christiansen J, Wicking C et al (1996) A mammalian patched homolog is expressed in target tissues of sonic hedgehog and maps to a region associated with developmental abnormalities. J Biol Chem 271:12125\u201312128","journal-title":"J Biol Chem"},{"key":"1996_CR4","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1126\/science.272.5268.1668","volume":"272","author":"RL Johnson","year":"1996","unstructured":"Johnson RL, Rothman AL, Xie J et al (1996) Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272:1668\u20131671","journal-title":"Science"},{"key":"1996_CR5","first-page":"2085","volume":"57","author":"T Pietsch","year":"1997","unstructured":"Pietsch T, Waha A, Koch A et al (1997) Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 57:2085\u20132088","journal-title":"Cancer Res"},{"key":"1996_CR6","first-page":"842","volume":"57","author":"C Raffel","year":"1997","unstructured":"Raffel C, Jenkins RB, Frederick L et al (1997) Sporadic medulloblastomas contain PTCH mutations. Cancer Res 57:842\u2013845","journal-title":"Cancer Res"},{"key":"1996_CR7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2009.03.007","volume":"30","author":"SJ Scales","year":"2009","unstructured":"Scales SJ, de Sauvage FJ (2009) Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 30:303\u2013312","journal-title":"Trends Pharmacol Sci"},{"key":"1996_CR8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.onc.1201340","volume":"15","author":"I Vorechovsk\u00fd","year":"1997","unstructured":"Vorechovsk\u00fd I, Tingby O, Hartman M et al (1997) Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene 15:361\u2013366","journal-title":"Oncogene"},{"key":"1996_CR9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature07275","volume":"455","author":"RL Yauch","year":"2008","unstructured":"Yauch RL, Gould SE, Scales SJ et al (2008) A paracrine requirement for hedgehog signalling in cancer. Nature 455:406\u2013410","journal-title":"Nature"},{"key":"1996_CR10","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","volume":"17","author":"PM LoRusso","year":"2011","unstructured":"LoRusso PM, Rudin CM, Reddy JC et al (2011) Phase 1 trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 17:2502\u20132511","journal-title":"Clin Cancer Res"},{"key":"1996_CR11","doi-asserted-by":"crossref","unstructured":"Sekulic A, Migden MR, Oro AE et al (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366:2171\u20132179","DOI":"10.1056\/NEJMoa1113713"},{"key":"1996_CR12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3109\/00498250903180289","volume":"39","author":"H Wong","year":"2009","unstructured":"Wong H, Chen JZ, Chou B et al (2009) Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor. Xenobiotica 39:850\u2013861","journal-title":"Xenobiotica"},{"key":"1996_CR13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2008.01.027","volume":"13","author":"H Kimura","year":"2008","unstructured":"Kimura H, Ng JM, Curran T (2008) Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell 13:249\u2013260","journal-title":"Cancer Cell"},{"key":"1996_CR14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/toxsci\/kfn076","volume":"104","author":"RJ Lipinski","year":"2008","unstructured":"Lipinski RJ, Hutson PR, Hannam PW et al (2008) Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the mouse. Toxicol Sci 104:189\u2013197","journal-title":"Toxicol Sci"},{"key":"1996_CR15","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/bdra.20656","volume":"88","author":"RJ Lipinski","year":"2010","unstructured":"Lipinski RJ, Song C, Sulik KK et al (2010) Cleft lip and palate results from Hedgehog signaling antagonism in the mouse: phenotypic characterization and clinical implications. Birth Defects Res A Clin Mol Teratol 88:232\u2013240","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"1996_CR16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2125.1999.00030.x","volume":"48","author":"SJ Baldwin","year":"1999","unstructured":"Baldwin SJ, Clarke SE, Chenery RJ (1999) Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 48:424\u2013432","journal-title":"Br J Clin Pharmacol"},{"key":"1996_CR17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/1078-0432.CCR-06-1947","volume":"13","author":"LD Yee","year":"2007","unstructured":"Yee LD, Williams N, Wen P et al (2007) Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res 13:246\u2013252","journal-title":"Clin Cancer Res"},{"key":"1996_CR18","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1528-1157.2003.55602.x","volume":"44","author":"DR Doose","year":"2003","unstructured":"Doose DR, Wang S-S, Padmanabhan M, Schwabe S, Jacobs P, Bialer M (2003) Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 44:540\u2013549","journal-title":"Epilepsia"},{"key":"1996_CR19","unstructured":"United States Food and Drug Administration (2012) Guidance for Industry. Drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations. U.S. Department of Health and Human Services, Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm292362.pdf . Accessed 17 Apr 2012"},{"key":"1996_CR20","unstructured":"Ortho-Novum\u00ae 1\/35 (2010) US prescribing information. Ortho-McNeil-Janssen Pharmaceuticals Inc., USA. http:\/\/www.janssenpharmaceuticalsinc.com\/assets\/orthonov.pdf . Accessed 6 Mar 2012"},{"key":"1996_CR21","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/1078-0432.CCR-10-2736","volume":"17","author":"RA Graham","year":"2011","unstructured":"Graham RA, Lum BL, Cheeti S et al (2011) Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res 17:2512\u20132520","journal-title":"Clin Cancer Res"},{"key":"1996_CR22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jchromb.2010.01.039","volume":"878","author":"X Ding","year":"2010","unstructured":"Ding X, Chou B, Graham RA et al (2010) Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:785\u2013790","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"suppl 8","key":"1996_CR23","first-page":"LBA25","volume":"21","author":"SB Kaye","year":"2010","unstructured":"Kaye SB, Fehrenbacher L, Holloway R et al (2010) A phase 2, randomized, placebo-controlled study of hedgehog (HH) pathway inhibitor GDC-0449 as maintenance therapy in patients with ovarian cancer in 2nd or 3rd complete remission (CR). Ann Oncol 21(suppl 8):LBA25","journal-title":"Ann Oncol"},{"key":"1996_CR24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2125.2007.03084.x","volume":"65","author":"E Andrews","year":"2008","unstructured":"Andrews E, Damle BD, Fang A et al (2008) Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. Br J Clin Pharmacol 65:531\u2013539","journal-title":"Br J Clin Pharmacol"},{"key":"1996_CR25","unstructured":"Jinteli\u2122 (2011) Prescribing information. Teva Pharmaceuticals US, Inc., USA. http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=d667ca75-1a17-43fc-9077-f25ce0908f8d . Accessed 6 Mar 2012"},{"key":"1996_CR26","unstructured":"Erivedge\u2122 (2012) Prescribing Information. Genentech Inc., USA. http:\/\/www.erivedge.com\/hcp\/prescribing-information.html . Accessed Apr 30, 2012"},{"key":"1996_CR27","unstructured":"United States Food and Drug Administration (2012) Guidance for industry. Drug interaction studies\u2014study design, data analysis, and implications for dosing and labeling. U.S. Department of Health and Human Services, Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm072101.pdf . Accessed 9 Jan 2012"},{"key":"1996_CR28","unstructured":"European Medicines Agency (2010) Guideline on the investigation of drug interactions (draft). http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/05\/WC500090112.pdf . Accessed 9 Jan 2012"},{"key":"1996_CR29","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1158\/1078-0432.CCR-11-0972","volume":"17","author":"PM LoRusso","year":"2011","unstructured":"LoRusso PM, Jimeno A, Dy G et al (2011) Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 17:5774\u20135782","journal-title":"Clin Cancer Res"},{"issue":"suppl 8","key":"1996_CR30","first-page":"LBA21","volume":"21","author":"JD Berlin","year":"2010","unstructured":"Berlin JD, Bendell J, Hart L et al (2010) A phase 2, randomized, double-blind, placebo controlled study of hedgehog pathway inhibitor (HPI) GDC-0449 in patients with previously untreated metastatic colorectal cancer (mCRC). Ann Oncol 21(suppl 8):LBA21","journal-title":"Ann Oncol"},{"key":"1996_CR31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0012-1606(02)00048-9","volume":"255","author":"JM Hall","year":"2003","unstructured":"Hall JM, Bell ML, Finger TE (2003) Disruption of sonic Hedgehog signaling alters growth and patterning of lingual taste papillae. Dev Biol 255:263\u2013277","journal-title":"Dev Biol"},{"key":"1996_CR32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ydbio.2004.07.042","volume":"276","author":"H-X Liu","year":"2004","unstructured":"Liu H-X, MacCallum DK, Edwards C, Gaffield W, Mistretta CM (2004) Sonic Hedgehog exerts distinct, stage-specific effects on tongue and taste papilla development. Dev Biol 276:280\u2013300","journal-title":"Dev Biol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1996-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-012-1996-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1996-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T05:29:57Z","timestamp":1714454997000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-1996-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,11]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["1996"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-1996-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,11]]}}}